Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jennifer Gray

Neuromuscular Medicine Port Jefferson, NY Doctor of Osteopathy

NPI 1669622080 CMS profile 1207943

200 Belle Terre Rd, Port Jefferson, NY 11777

Open in the dashboard

General payments

$664

19 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jennifer Gray of Port Jefferson, NY is reported in the CMS Open Payments database as having received $664 across 19 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $352 4
2022 General $58 2
2021 General $107 7
2020 General $66 4
2019 General $80 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Gray
  • Neuromuscular Medicine median
  • Middle half of Neuromuscular Medicine
  • National median

In program year 2025, general payments to Jennifer Gray were reported at $0. Among 29 Neuromuscular Medicine profiles paid that year, the median was $140 and the middle half received between $45 and $721.

Show as a table
Year Jennifer Gray Neuromuscular Medicine median Middle half National median
2019 $80 $106 $32–$174 $163
2020 $66 — — $114
2021 $107 $142 $72–$2,438 $132
2022 $58 $146 $37–$459 $149
2023 $0 $125 $25–$296 $160
2024 $352 $182 $50–$398 $164
2025 $0 $140 $45–$721 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. PTC Therapeutics, Inc. $144 4 payments
  2. Argenx US, Inc. $119 1 payment
  3. Microtransponder, Inc. $111 1 payment
  4. Celgene Corporation $88 1 payment
  5. E.R. Squibb & Sons, L.L.C. $56 4 payments
  6. Alkermes, Inc. $34 1 payment
  7. Janssen Pharmaceuticals, Inc $31 2 payments
  8. Allergan Inc. $29 2 payments
  9. Sarepta Therapeutics, Inc. $28 1 payment
  10. Akcea Therapeutics, Inc. $14 1 payment
  11. Other $10 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $664 19 payments
Products named General payments · program years 2019–2024
  1. EMFLAZA $144 4 payments
  2. VYVGART $119 1 payment
  3. ZEPOSIA $88 1 payment
  4. ELIQUIS $56 4 payments
  5. LYBALVI $34 1 payment
  6. ARISTADA Cns $34 1 payment
  7. ARISTADA Cns $34 1 payment
  8. ARISTADA Cns $34 1 payment
  9. ARISTADA Cns $34 1 payment
  10. XARELTO $31 2 payments
  11. Other $80 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

24

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$576

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

45.8%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tramadol Hcl Er Tramadol Hcl Brand 11 $570
Tramadol Hcl Generic 13 $6

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$176,242

Of which drugs: $98,872

Medicare patients

244

Average age 73

Services billed

23,247

115 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Ischemic heart disease 53%
Diabetes 41%
Depression 39%
Chronic kidney disease 32%
Atrial fibrillation 29%
Heart failure 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 18 13,750 $66,300

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYVGART
  • ARGENX US, INC. $119
$119 — —
ZEPOSIA
  • Celgene Corporation $88
$88 — —
ARISTADA
  • Alkermes, Inc. $28
$28 — —
LYBALVI
  • Alkermes, Inc. $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

19 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neuromuscular Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record